Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

1.210 -0.030 (-2.42%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	58,390
Open	1.220
Bid (Size)	1.230 (200)
Ask (Size)	1.250 (200)
Prev. Close	1.240
Today's Range	1.130 - 1.308
52wk Range	1.130 - 33.25
Shares Outstanding	171,350,166
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

November 20, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 19, 2025

Via Benzinga

Performance

YTD	-95.6%	-95.6%
1 Month	-36.0%	-36.0%
3 Month	-32.8%	-32.8%
6 Month	-73.1%	-73.1%
1 Year	-95.1%	-95.1%

More News

Tuesday's after hours session: top gainers and losers ↗

November 18, 2025

Via Chartmill

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

November 17, 2025

Via ACCESS Newswire

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

Earnings Preview For Jaguar Health ↗

August 13, 2025

Via Benzinga

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

November 14, 2025

Via ACCESS Newswire

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

November 13, 2025

Via ACCESS Newswire

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and

November 06, 2025

Via ACCESS Newswire

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 24, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 09, 2025

Via Benzinga

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

October 06, 2025

Via ACCESS Newswire

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

September 30, 2025

Via ACCESS Newswire

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

September 25, 2025

Via ACCESS Newswire

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

September 24, 2025

Via ACCESS Newswire

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

September 23, 2025

Via ACCESS Newswire

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

September 05, 2025

Via ACCESS Newswire

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

August 21, 2025

Via ACCESS Newswire

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

August 19, 2025

Via ACCESS Newswire

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

August 19, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 14, 2025

Via Benzinga

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

August 14, 2025

Via ACCESS Newswire

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

August 12, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 14, 2025

Via Benzinga

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

July 10, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?

Yes, Jaguar Health, Inc. - Common Stock is publicly traded.

What exchange does Jaguar Health, Inc. - Common Stock trade on?

Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jaguar Health, Inc. - Common Stock?

The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market

What is the current price of Jaguar Health, Inc. - Common Stock?

The current price of Jaguar Health, Inc. - Common Stock is 1.210

When was Jaguar Health, Inc. - Common Stock last traded?

The last trade of Jaguar Health, Inc. - Common Stock was at 11/21/25 04:00 PM ET

What is the market capitalization of Jaguar Health, Inc. - Common Stock?

The market capitalization of Jaguar Health, Inc. - Common Stock is 207.33M

How many shares of Jaguar Health, Inc. - Common Stock are outstanding?

Jaguar Health, Inc. - Common Stock has 207M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.